Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl- anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10

Biochemical Pharmacology

Volumn 82, Issue 6, 2011, Pages 632-641

  Hertenstein, Anne ^a,b   Schumacher, Theresa ^a,b   Litzenburger, Ulrike ^a,b   Opitz, Christiane A ^a,b   Falk, Christine S ^c,d   Serafini, Tito ^e   Wick, Wolfgang ^a,b   Platten, Michael ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e Nuon Therapeutics Inc   (United States)

Author keywords

Anti allergic drug; Multiple sclerosis; Rheumatoid arthritis; T cell; Tryptophan catabolism

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANILAST;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR;

EID: 80051549284     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.013     Document Type: Article

References (53)

1. L. Steinman A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage Nat Med 13 2007 139 145
2. T. Korn, E. Bettelli, M. Oukka, and V.K. Kuchroo IL-17 and Th17 cells Annu Rev Immunol 27 2009 485 517
3. B.W. van Oosten, M. Lai, S. Hodgkinson, F. Barkhof, D.H. Miller, and I.F. Moseley Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial Neurology 49 1997 351 357
4. M.H. Rep, B.W. van Oosten, M.T. Roos, H.J. Ader, C.H. Polman, and R.A. van Lier Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans J Clin Invest 99 1997 2225 2231 (Pubitemid 27203779)
5. K. O'Brien, B. Gran, and A. Rostami T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis Immunotherapy 2 2010 99 115
6. J.J. O'Shea, and W.E. Paul Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells Science 327 2010 1098 1102
7. J. Zhu, H. Yamane, and W.E. Paul Differentiation of effector CD4T cell populations (*) Annu Rev Immunol 28 2010 445 489
8. A.S. Adamson, K. Collins, A. Laurence, and J.J. O'Shea The Current STATus of lymphocyte signaling: new roles for old players Curr Opin Immunol 21 2009 161 166
9. G. Frisullo, F. Angelucci, M. Caggiula, V. Nociti, R. Iorio, and A.K. Patanella pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity J Neurosci Res 84 2006 1027 1036 (Pubitemid 44521047)
10. G. Frisullo, V. Nociti, R. Iorio, A.K. Patanella, D. Plantone, and A. Bianco T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity Clin Exp Immunol 158 2009 106 114
11. F. Madia, G. Frisullo, V. Nociti, A. Conte, M. Luigetti, and A. Del Grande pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy J Peripher Nerv Syst 14 2009 107 117
12. T. Nishibori, Y. Tanabe, L. Su, and M. David Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease J Exp Med 199 2004 25 34 (Pubitemid 38076475)
13. E. Bettelli, B. Sullivan, S.J. Szabo, R.A. Sobel, L.H. Glimcher, and V.K. Kuchroo Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis J Exp Med 200 2004 79 87 (Pubitemid 38924730)
14. D. Caretto, S.D. Katzman, A.V. Villarino, E. Gallo, and A.K. Abbas Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells J Immunol 184 2010 30 34
15. M. Hara, K. Ono, M.W. Hwang, A. Iwasaki, M. Okada, and K. Nakatani Evidence for a role of mast cells in the evolution to congestive heart failure J Exp Med 195 2002 375 381 (Pubitemid 34461496)
16. J.J. Inglis, G. Criado, M. Andrews, M. Feldmann, R.O. Williams, and M.L. Selley The anti-allergic drug, N-(3′,4′-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis Rheumatology (Oxford) 46 2007 1428 1432 (Pubitemid 47317088)
17. T. Nagate, T. Tamura, F. Sato, J. Kuroda, J. Nakayama, and N. Shibata Tranilast suppresses the disease development of the adjuvant- and streptococcal cell wall-induced arthritis in rats J Pharmacol Sci 105 2007 48 56 (Pubitemid 47463524)
18. M. Platten, P.P. Ho, S. Youssef, P. Fontoura, H. Garren, and E.M. Hur Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite Science 310 2005 850 855 (Pubitemid 41567343)
19. N. Shiota, P.T. Kovanen, K.K. Eklund, N. Shibata, K. Shimoura, and T. Niibayashi The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice Br J Pharmacol 159 2010 626 635
20. D. Whiting, G. Hsieh, J.J. Yun, A. Banerji, W. Yao, and M.C. Fishbein Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production J Immunol 172 2004 7417 7424 (Pubitemid 38747603)
21. S. Watanabe, A. Matsuda, Y. Suzuki, K. Kondo, Y. Ikeda, and H. Hashimoto Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors Br J Pharmacol 130 2000 307 314 (Pubitemid 30261040)
22. A. Takahashi, T. Taniguchi, Y. Ishikawa, and M. Yokoyama Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53 Circ Res 84 1999 543 550 (Pubitemid 29138591)
23. S. Koyama, H. Takagi, A. Otani, K. Suzuma, K. Nishimura, and Y. Honda Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells Br J Pharmacol 127 1999 537 545 (Pubitemid 29245694)
24. H. Inoue, H. Ohshima, H. Kono, M. Yamanaka, T. Kubota, and M. Aihara Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin-1beta-stimulated fibroblasts Biochem Pharmacol 53 1997 1941 1944 (Pubitemid 27356068)
25. M.J. Charng, and C.H. Wu Transcriptional activation of p21 by Tranilast is mediated via transforming growth factor beta signal pathway Br J Pharmacol 147 2006 117 124
26. M. Platten, C. Wild-Bode, W. Wick, J. Leitlein, J. Dichgans, and M. Weller N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells Int J Cancer 93 2001 53 61 (Pubitemid 32539501)
27. G.J. Prud'homme, Y. Glinka, A. Toulina, O. Ace, V. Subramaniam, and S. Jothy Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist PLoS ONE 5 2010 e13831
28. K. Izumi, A. Mizokami, T. Shima, K. Narimoto, K. Sugimoto, and Y. Kobori Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer Anticancer Res 30 2010 3077 3081
29. J. Soma, K. Sato, H. Saito, and Y. Tsuchiya Effect of tranilast in early-stage diabetic nephropathy Nephrol Dial Transplant 21 2006 2795 2799 (Pubitemid 44542233)
30. D.R. Holmes Jr. , M. Savage, J.M. LaBlanche, L. Grip, P.W. Serruys, and P. Fitzgerald Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial Circulation 106 2002 1243 1250 (Pubitemid 34988643)
31. M. Spiecker, I. Lorenz, N. Marx, and H. Darius Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells Mol Pharmacol 62 2002 856 863
32. A. Boasso, J.P. Herbeuval, A.W. Hardy, C. Winkler, and G.M. Shearer Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells Blood 105 2005 1574 1581 (Pubitemid 40223677)
33. G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G.B. Ferrara Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J Exp Med 196 2002 459 468
34. C.A. Opitz, W. Wick, L. Steinman, and M. Platten Tryptophan degradation in autoimmune diseases Cell Mol Life Sci 64 2007 2542 2563 (Pubitemid 350035605)
35. Y. Kawano, and T. Noma Cell action mechanism of tranilast - effect on the expression of HLA-class II antigen Int J Immunopharmacol 15 1993 487 500 (Pubitemid 23179275)
36. B.T. Rouse, and S. Sehrawat Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 10 2010 514 526
37. W. Reith, S. LeibundGut-Landmann, and J.M. Waldburger Regulation of MHC class II gene expression by the class II transactivator Nat Rev Immunol 5 2005 793 806 (Pubitemid 41400853)
38. M. Platten, W. Wick, J. Wischhusen, and M. Weller N-[3,4- dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma) Br J Pharmacol 134 2001 1279 1284 (Pubitemid 33097258)
39. M. Platten, K. Eitel, J. Wischhusen, J. Dichgans, and M. Weller Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) Biochem Pharmacol 66 2003 1263 1270 (Pubitemid 37130301)
40. S. Lacotte, S. Brun, S. Muller, and H. Dumortier CXCR3, inflammation, and autoimmune diseases Ann N Y Acad Sci 1173 2009 310 317
41. R. Sporici, and T.B. Issekutz CXCR3 blockade inhibits T-cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease Eur J Immunol 40 2010 2751 2761
42. J. Ni, Y.N. Zhu, X.G. Zhong, Y. Ding, L.F. Hou, and X.K. Tong The chemokine receptor antagonist TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function Br J Pharmacol 158 2009 2046 2056
43. R.E. Kohler, I. Comerford, S. Townley, S. Haylock-Jacobs, I. Clark-Lewis, and S.R. McColl Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis Brain Pathol (Zurich, Switzerland) 18 2008 504 516
44. K. Mohan, and T.B. Issekutz Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis J Immunol 179 2007 8463 8469
45. J.H. Xie, N. Nomura, M. Lu, S.L. Chen, G.E. Koch, and Y. Weng Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation J Leukoc Biol 73 2003 771 780 (Pubitemid 38040456)
46. M. Muller, S.L. Carter, M.J. Hofer, P. Manders, D.R. Getts, and M.T. Getts CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system J Immunol 179 2007 2774 2786
47. L. Liu, D. Huang, M. Matsui, T.T. He, T. Hu, and J. Demartino Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis J Immunol 176 2006 4399 4409 (Pubitemid 44264420)
48. J.M. Rosenblum, N. Shimoda, A.D. Schenk, H. Zhang, D.D. Kish, and K. Keslar CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors J Immunol 184 2010 3450 3460
49. E.Y. Lee, Z.H. Lee, and Y.W. Song CXCL10 and autoimmune diseases Autoimmun Rev 8 2009 379 383
50. W.P. Kuan, L.S. Tam, C.K. Wong, F.W. Ko, T. Li, and T. Zhu CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis J Rheumatol 37 2010 257 264
51. T. Loos, L. Dekeyzer, S. Struyf, E. Schutyser, K. Gijsbers, and M. Gouwy TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis Lab Invest 86 2006 902 916 (Pubitemid 44268165)
52. D.J. Mahad, S.J. Howell, and M.N. Woodroofe Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis J Neurol Neurosurg Psychiatry 72 2002 498 502
53. T.L. Sorensen, M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, and V.A. Folcik Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients J Clin Invest 103 1999 807 815 (Pubitemid 29152626)